Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients | Completed | Obesity | Drug, Drug - exenatide, placebo | AstraZeneca, Eli Lilly and Company, Industry, Industry | 18 Years - N/A | Phase 2 | Interventional | This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects. | ||
Clinicaltrials.gov | An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED) | Terminated | Obesity | Drug, Drug - taranabant, placebo | Merck Sharp & Dohme Corp., Industry | 18 Years - N/A | Phase 3 | Interventional | A 1 year worldwide study in obese and overweight patients to assess the safety and effect on body weight of an investigational weight loss drug. | ||
|
Clinicaltrials.gov | The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes | Enrolling by invitation | Obesity | Drug, Drug, Drug, Drug - SHR20004, SHR20004, SHR20004, placebo | Jiangsu HengRui Medicine Co., Ltd., Industry | 18 Years - 65 Years | Phase 2 | Interventional | The study is being conducted to assess the efficacy and safety of SHR20004 on body weight in obese subjects without diabetes. | ||
|
Clinicaltrials.gov | The Possible Effects of Roflumilast on Obesity Related Disorders | Recruiting | Obesity, PreDiabetes | Drug, Drug - Roflumilast, placebo | Tanta University, Other | 25 Years - 65 Years | Phase 3 | Interventional | Evaluation of the possible effects of roflumilast on weight, glucose and lipid metabolism, insulin resistance, oxidative stress and inflammatory process in prediabetic obese subjects. | ||
|
Clinicaltrials.gov | The Role of Microbiome in Recurrent Obesity | Not yet recruiting | Obesity, Weight Loss, FMT | Other, Other - Fecal microbiome transplant, placebo | Eran Elinav, Assaf-Harofeh Medical Center, Other, Other | 18 Years - 65 Years | N/A | Interventional | This past century witnessed a significant increase in the prevalence of obesity. successful maintenance of weight loss is defined as losing at least 10% of the initial body weight and maintaining it for at least one year. However, keeping the low body weight is rarely maintained, as 80% of people who lost 10% of their body weight will return to their initial weight within a year. Although there is no agreement as to what contributes to the recurrent weight regain phenomenon (also known as 'weight cycling' or 'yo-yo diet'), it is strongly associated with the risk of developing metabolic risk factors and their complications including heart disease and all-cause mortality. Altering the gut microbiota is one method to treat disease states associated with gut bacteria. For instance, fecal microbiota transplant (FMT) or fecal bacteriotherapy, is the process of transferring stool from a healthy donor to another. Although numerous individual microbes have been identified as related to obesity, multiple studies suggest that loss of microbial diversity has a stronger impact on the development of metabolic dysfunction, this diversity may be restored by FMT. This study will determine whether microbiome modulation might be a possible future target against recurrent obesity in humans and whether orally administered FMT from a lean donor, post weight loss might be an effective intervention to prevent weight regain. | ||
|
Clinicaltrials.gov | The Effect of Intervention With Probiotic K56 on Body Fat Reduction in Obese Subjects | Recruiting | Obesity | Dietary Supplement, Dietary Supplement - Lactobacillus paracasei K56, placebo | Fudan University, Inner Mongolia Yili Industrial Group Co., Ltd, Other, Industry | 40 Years - 65 Years | N/A | Interventional | The aim of the present study was to investigate the effect of intervention with Lactobacillus paracasei K56 on body fat, metabolic risk markers,inflammatory markers and gut microbiota composition in obesity. | ||
|
Clinicaltrials.gov | A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years | Completed | Metabolism and Nutrition Disorder, Obesity | Drug, Drug - liraglutide, placebo | Novo Nordisk A/S, Industry | 7 Years - 11 Years | Phase 1 | Interventional | This trial is conducted in the United States of America. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of liraglutide in obese children aged 7 to 11 years | ||
|
Clinicaltrials.gov | Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes | Completed | Overweight, Obesity | Device, Device - Gelesis100, placebo | Gelesis, Inc., Industry | 22 Years - 65 Years | N/A | Interventional | This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes. | ||
|
Clinicaltrials.gov | Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects | Completed | Metabolism and Nutrition Disorder, Obesity | Drug, Drug - NNC0174-0833, placebo | Novo Nordisk A/S, Industry | Male | 22 Years - 64 Years | Phase 1 | Interventional | This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics of single doses of NNC0174-0833 in normal weight, overweight to obese but otherwise healthy male subjects. | |
|
Clinicaltrials.gov | Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes | Completed | Dysglycemia, Obesity | Dietary Supplement, Other - Cinnamon, placebo | Joslin Diabetes Center, Kyunghee University, Other, Other | 20 Years - 70 Years | Phase 2 | Interventional | The transition from normal glucose tolerance to overt type 2 diabetes mellitus (T2D) encompasses a variety of glycemic abnormalities that are commonly referred to as 'prediabetes'. While intensive lifestyle interventions are the cornerstone of T2D prevention, developing safe, cost-effective adjunct therapeutic strategies is a clinically relevant goal. Cinnamon supplementation has been shown to improve fasting plasma glucose in patients with T2D. This placebo-controlled, randomized study will determine if cinnamon improves glucose homeostasis in patients with prediabetes over a 12-week period. | ||
|
Clinicaltrials.gov | Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo | Completed | Diabetes, Metabolism and Nutrition Disorder, Obesity | Drug, Drug - semaglutide, placebo | Novo Nordisk A/S, Industry | 18 Years - N/A | Phase 1 | Interventional | This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects compared with placebo. | ||
|
Clinicaltrials.gov | Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer | Completed | Breast Cancer, Obesity | Drug, Other, Other - metformin hydrochloride, placebo, laboratory biomarker analysis | Anna Maria Storniolo, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 75 Years | Early Phase 1 | Interventional | This randomized clinical trial studies metformin hydrochloride in overweight or obese patients at elevated risk for breast cancer. Metformin hydrochloride may decrease the expression of early tumor makers in breast tissue of patients at increased risk for breast cancer | |
|
Clinicaltrials.gov | Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children | Completed | Hyperhomocysteinemia, Obesity | Drug, Drug - Folic Acid, placebo | Queen Sirikit National Institute of Child Health, Chulalongkorn University, Other, Other | 9 Years - 18 Years | Phase 4 | Interventional | The purpose of the present study was to determine whether folic acid supplementation could reduce plasma homocysteine in obese children and to determine the association between dietary folate, serum folate and homocysteine level through the randomized double blinded placebo controlled trial. | ||
|
Clinicaltrials.gov | Effect of Physical Activity an Stress in Children | Completed | Obesity, Children, Physical Activity, Stress, Snacking | Behavioral, Behavioral - Acute physical activity intervention, placebo | University of Lausanne Hospitals, Other | 7 Years - 10 Years | N/A | Interventional | The objective of the study is to evaluate the impact of physical activity in obese and nonobese prepubertal children on: 1. biological stress responses during a psychosocial stress test 2. snacking and feeling of hunger in response to the same psychosocial stress test 3. the moderating factor of attachment on the biological stress responses and on snacking Children will be investigated on one study day during 3.5 hours. | ||
|
Clinicaltrials.gov | Pioglitazone on Pancreatic Steatosis and Bone Health | Completed | Obesity, Type 2 Diabetes | Drug, Drug - pioglitazone, placebo | University of Texas Southwestern Medical Center, National Institutes of Health (NIH), Other, NIH | 21 Years - 99 Years | N/A | Interventional | Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers. | ||
|
Clinicaltrials.gov | Effect of Resvida, a Comparison With Calorie Restriction Regimen | Completed | Obesity, Metabolic Syndrome, Diabetes, Aging | Dietary Supplement, Other, Behavioral - resveratrol, placebo, Calorie Restriction | Washington University School of Medicine, DSM Nutritional Products, Inc., Other, Industry | Female | 35 Years - 70 Years | N/A | Interventional | The purpose of this study is to compare the effects of the antioxidant "resveratrol" to a diet intervention (Calorie Restriction) to determine how each of them affects the following: gene expression profile, cholesterol (lipids), how well the hormone insulin works to control your blood sugar, and other blood and tissue markers of metabolic and cardiovascular health. Resveratrol is found in grape skin, wine, peanuts, and mulberries and is thought to have health benefits such as improving fat metabolism, insulin action, and possibly extending lifespan. Resvida™ is the name for the dietary supplement containing the natural antioxidant "resveratrol". Resvida™ will be supplied by DSM Nutritional Products, Ltd. Resvida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The makers of Resvida™ make no claim that this supplement is meant to treat any ailment. Calorie restriction (CR) is a low calorie diet (about 30% fewer calories than the American Dietetic Association (ADA) recommends). Calorie restriction has also been linked to health benefits (enhanced cardiovascular and metabolic health) and an extended lifespan. This study is designed to compare the health benefits of both resveratrol and CR and to determine if resveratrol mimics some of the health benefits shown with CR. | |
|
Clinicaltrials.gov | Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects | Completed | Obesity, Overweight | Drug, Drug, Drug, Drug, Drug, Drug - AC2307, placebo, AC2307, placebo, AC2307, placebo | AstraZeneca, Industry | 18 Years - 65 Years | Phase 2 | Interventional | A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects. | ||
|
Clinicaltrials.gov | Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | Completed | Metabolism and Nutrition Disorder, Obesity | Drug, Drug - liraglutide, placebo | Novo Nordisk A/S, Industry | 18 Years - N/A | Phase 3 | Interventional | This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pressure) or dyslipidaemia (an abnormal amount of lipids in the blood). Trial has following trial periods: A 12-week run-in period (from week -12 to week 0) followed by a 56-week main trial period (weeks 0-56) and a 12-week follow-up period (weeks 56-68). | ||
|
Clinicaltrials.gov | Efficacy Study of Betahistine on Body Weight in Obese Female Subjects | Completed | Obesity | Drug, Drug, Drug - betahistine dihydrochloride, betahistine dihydrochloride, placebo | OBEcure Ltd., International Antiviral Therapy Evaluation Center, Industry, Other | Female | 18 Years - 50 Years | Phase 2 | Interventional | The purpose of this study is to examine the effect of betahistine on body weight in obese female subjects | |
|
Clinicaltrials.gov | Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers | Completed | Obesity | Drug, Drug, Drug, Drug - CP-866,087, CP-866,087, CP-866,087, placebo | Pfizer, Industry | 18 Years - 65 Years | Phase 2 | Interventional | The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
